|
 |
 |
 |
 |
 |
 |
 |
 |
 |
Select publications
Bast A et al. Protectors against doxorubicin-induced cardiotoxicity: Flavonoids. Cell Biol Toxicol 2007;23(1):39-47. Abstract
Budman DR et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst 1998;90(16):1205-11. Abstract
Dang C et al. Mature cardiac safety results of dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) with trastuzumab (H) in HER2/neu overexpressed/amplified breast cancer (BCA). San Antonio Breast Cancer Symposium 2006a; Abstract 2101.
Dang C et al. Updated cardiac safety results of dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) with trastuzumab (H) in HER2/neu overexpressed/amplified breast cancer (BCA). Proc ASCO 2006b;Abstract 582.
Doyle JJ et al. Chemotherapy and cardiotoxicity in older breast cancer patients: A population-based study. J Clin Oncol 2005;23(34):8597-605. Abstract
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005;365(9472):1687-717. Abstract
Ewer MS et al. Reversibility of trastuzumab-related cardiotoxicity: New insights based on clinical course and response to medical treatment. J Clin Oncol 2005;23(31):7820-6. Abstract
Giordano SH et al. Congestive heart failure (CHF) in older women treated with anthracycline (A) chemotherapy (C). Proc ASCO 2006; Abstract 521.
Heidenreich PA et al. Asymptomatic cardiac disease following mediastinal irradiation. J Am Coll Cardiol 2003;42(4):743-9. Abstract
Jensen BV. Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer. Semin Oncol 2006;33(3 Suppl 8):15-21. Abstract
Jones RL et al. Anthracycline cardiotoxicity. Expert Opin Drug Saf 2006;5(6):791-809. Abstract
Jones SE et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 2006;24:5381-7. Abstract
Levine MN et al; National Cancer Institute of Canada Clinical Trials Group. Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: Update of National Cancer Institute of Canada Clinical Trials Group Trial MA5. J Clin Oncol 2005;23(22):5166-70. Abstract
McArthur HL et al. A population-based study of adjuvant trastuzumab-mediated cardiotoxicity among early stage HER-2+ breast cancer patients. San Antonio Breast Cancer Symposium 2006; Abstract 2098.
Ng R et al. Anticancer agents and cardiotoxicity. Semin Oncol 2006;33(1):2-14. Abstract
Pegram M et al. Phase II combined biological therapy targeting the HER2 proto-oncogene and the vascular endothelial growth factor using trastuzumab (T) and bevacizumab (B) as first line treatment of HER2-amplified breast cancer. San Antonio Breast Cancer Symposium 2006; Abstract 301.
Piccart-Gebhart MJ et al; Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER 2-positive breast cancer. N Engl J Med 2005;353(16):1659-72. Abstract
Pritchard KI et al; National Cancer Institute of Canada Clinical Trials Group. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 2006;354(20):2103-11. Abstract
Romond EH et al. Trastuzumab plus adjuvant chemotherapy for operable HER 2-positive breast cancer. N Engl J Med 2005;353(16):1673-84. Abstract
Routledge HC et al. Monitoring the introduction of new drugs — Herceptin to cardiotoxicity. Clin Med 2006;6(5):478-81. Abstract
Shepherd LE et al. Left ventricular function following adjuvant chemotherapy for breast cancer: The NCIC CTG MA5 experience. Proc ASCO 2006;Abstract 522.
Slamon D et al. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC 
T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients. San Antonio Breast Cancer Symposium 2006; Abstract 52.
Slamon D et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. San Antonio Breast Cancer Symposium 2005; Abstract 1.
Slamon DJ et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344(11):783-92. Abstract
Sledge GW et al. Adjuvant trastuzumab: Long-term results of E2198. San Antonio Breast Cancer Symposium 2006;Abstract 2075.
Smith I et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial. Lancet 2007;369(9555):29-36. Abstract
Smith KL et al. Cardiac dysfunction associated with trastuzumab. Expert Opin Drug Saf 2006;5(5):619-29. Abstract
Tan-Chiu E et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005;23(31):7811-9. Abstract
 |
 |
